Amita Patnaik

1. First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.
   2024/06/01 by Timothy A. Yap, Nehal J. Lakhani, Amita Patnaik +20 · 1 citation
   Biochemistry, Genetics and Molecular Biology · Medicine · #DNA Repair Mechanisms #PARP inhibition in cancer therapy #Radiation Therapy and Dosimetry